Who Paid My Doc
Sam Gumbert
Critical Care Medicine Washington, DC Medical Doctor
NPI 1629393996 CMS profile 346535
900 23Rd St Nw Ste G-2092, Washington, DC 20037
General payments
$96
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sam Gumbert of Washington, DC is reported in the CMS Open Payments database as having received $96 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18 | 1 | |
| 2024 | General | $78 | 1 |
Beside peers
- Sam Gumbert
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Sam Gumbert were reported at $18. Among 445 Critical Care Medicine profiles paid that year, the median was $97 and the middle half received between $33 and $255.
Show as a table
| Year | Sam Gumbert | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $103 | $29–$256 | $163 |
| 2020 | $0 | $60 | $22–$164 | $114 |
| 2021 | $0 | $115 | $30–$249 | $132 |
| 2022 | $0 | $97 | $27–$196 | $149 |
| 2023 | $0 | $104 | $31–$245 | $160 |
| 2024 | $78 | $93 | $28–$268 | $164 |
| 2025 | $18 | $97 | $33–$255 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$45,031
Medicare patients
256
Services billed
286
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Chronic kidney disease | 37% | |
| Ischemic heart disease | 36% | |
| Atrial fibrillation | 32% | |
| Diabetes | 31% | |
| Heart failure | 30% | |
| Depression | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in District of Columbia
Jonathan Chow
Critical Care Medicine · Washington, DC
Beverly Chang
Critical Care Medicine · Washington, DC
Jeffrey Plotkin
Critical Care Medicine · Washington, DC
Matthew Mueller
Critical Care Medicine · Washington, DC
Duane Stillions
Critical Care Medicine · Washington, DC
Jessica Sumski
Critical Care Medicine · Washington, DC
Related records
Critical Care Medicine in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.